Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 7/20 | 0.37 |
| ▸ | HCK | P08631 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | REN | P00797 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9864881 | 0.98 | ACE (0.36) | ACEHCKFLT3 | |
| SCHEMBL1979266 | 0.94 | CNR2 (0.37) | ACE | |
| SCHEMBL206311 | 0.93 | ACE (0.42) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL15664979 | 0.93 | ACE (0.42) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL2494405 | 0.93 | ACE (0.42) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL3732799 | 0.92 | CNR2 (0.36) | ACE | |
| SCHEMBL1952767 | 0.91 | ACE (0.41) | ACEREN | |
| SCHEMBL9107688 | 0.91 | ACE (0.41) | ACEREN | |
| SCHEMBL28152132 | 0.91 | ACE (0.43) | ACERENLMNACYP2C19HSD17B10 | |
| SCHEMBL2223045 | 0.91 | ACE (0.43) | ACERENLMNACYP2C19HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088890-B2 | Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2012-01-03 | — | — | US | claimed |
| EP-2334324-A2 | BBETA (15-42) AND ITS ANALOGUES COMBINED WITH CYCLOSPORINE FOR TREATMENT OF REPERFUSION INJURY | Fibrex Medical Research & Development GmbH (AT) | 2011-06-22 | — | — | EP | claimed |
| EP-2328925-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | Fibrex Medical Research & Development GmbH (AT) | 2011-06-08 | — | — | EP | claimed |
| US-7884074-B2 | Compounds and methods for prevention and/or treatment of inflammation using the same | Ikaria Development Subsidiary Two, LLC (US) | 2011-02-08 | — | — | US | claimed |
| EP-2274328-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | Fibrex Medical Research & Development GmbH (AT) | 2011-01-19 | — | — | EP | claimed |
| US-20100099602-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF HYPOXIC INJURY | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-22 | — | — | US | claimed |
| WO-2010043972-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF HYPOXIC INJURY | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-22 | — | — | WO | claimed |
| WO-2010034041-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-01 | — | — | WO | claimed |
| US-20100081787-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-01 | — | — | US | claimed |
| US-20090286739-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2009-11-19 | — | — | US | claimed |
| WO-2009137850-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2009-11-19 | — | — | WO | claimed |
| US-20080161232-A1 | C5a is a cleavage product of the complement cascade, the CS convertase; antiinflammatory agents; autoimmune diseases; cyclic peptide compounds | JERINI AG (DE) | 2008-07-03 | — | — | US | claimed |
| CN-101146529-A | Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-19 | — | — | CN | claimed |
| CN-101107264-A | C5a receptor antagonists | JERINI AG (DE) | 2008-01-16 | — | — | CN | claimed |
| EP-1838725-A1 | C5A RECEPTOR ANTAGONISTS | Jerini AG (DE) | 2007-10-03 | — | — | EP | claimed |
| US-20060183883-A1 | C5a Receptor antagonists | JERINI AG (DE) | 2006-08-17 | — | — | US | claimed |
| WO-2006074964-A1 | C5A RECEPTOR ANTAGONISTS | JERINI AG (DE) | 2006-07-20 | — | — | WO | claimed |
| EP-4153310-B1 | BBETA-15-42 FOR THE TREATMENT OF VIRAL ENDOTHELITIS | F4 PHARMA GMBH (AT) | 2026-02-18 | — | — | EP | disclosed |
| WO-2006074964-A1 | C5A RECEPTOR ANTAGONISTS | JERINI AG (DE) | 2006-07-20 | — | — | WO | disclosed |
| US-4879403-A | AMINATION, CRYSTALLIZATION | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099602-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF HYPOXIC INJURY | HIF1AN, HIF1A, EGLN3 | ACE 1447/4885HCK 4428/4885FLT3 3415/4885 |
| US-20060183883-A1 | C5a Receptor antagonists | C5AR1, C3AR1, C5AR2 | ACE 1364/4885HCK 703/4885FLT3 335/4885 |
| US-20100081787-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | NGLY1, GHRHR, GHSR | ACE 4569/4885HCK 3333/4885FLT3 862/4885 |
| US-20080161232-A1 | C5a is a cleavage product of the complement cascade, the CS convertase; antiinflammatory agents; autoimmune diseases; cyclic peptide compounds | C3AR1, C5, C5AR1 | ACE 517/4885HCK 715/4885FLT3 885/4885 |
| US-20090286739-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | NPR3, RXFP3, RXFP1 | ACE 4484/4885HCK 3893/4885FLT3 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.